Recruiting
Sponsor: Massachusetts General Hospital
Collaborators: Novartis
Information provided by (Responsible party): Principal Investigator Massachusetts General Hospital Zofia Piotrowska Principal Investigator
ClinicalTrials.gov Identifier: NCT03292133
Progression Free Survival at 9 months [Time Frame: 9 months] [Designated as safety issue: ]
Response Rate [Time Frame: 2 years] [Designated as safety issue: ]
Overall Survival [Time Frame: 2 years] [Designated as safety issue: ]
Safety and Tolerability of the EGF816/gefitinib combination (Summary of the adverse events experienced by study participants as evaluated by CTCAE v4) [Time Frame: 2 years] [Designated as safety issue: ]
Ages Eligible for Study: N/A-N/A
Genders Eligible for Study: All
Accepts Healthly Volunteers: No
Massachusetts General Hospital
Novartis
No publications provided
Lung Cancer
Lung Neoplasms
Gefitinib
(R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo(d)imidazol-2-yl)-2-methylisonicotinamide
ClinicalTrials.gov processed this data on February 25, 2021